News | April 17, 2013

MDCT Better Determines Transcatheter Aortic Valve Implant Size

Study looks at patients who underwent an MDCT scan and transthoracic and transesophageal echocardiography before having a TAVI

April 17, 2013 — Multi-detector computed tomography (MDCT) is a better way to measure annular size in patients with aortic stenosis who are candidates for transcatheter aortic valve implantation (TAVI) than two dimensional echocardiography according to a new study.

The study included 69 patients who underwent an MDCT scan as well as transthoracic and transesophageal echocardiography before having a TAVI. TAVI is done to treat patients with severe aortic stenosis who are not surgical candidates. Aortic stenosis is a common disorder in the elderly.

"Measurement of the aortic annulus is crucial for implant size selection and procedure success," said Vineeta Sethi, M.D., lead author of the study. "If the implanted valve is too small, blood will leak outside of the valve apparatus back into the heart."

Measurements obtained on MDCT were significantly different than those obtained on echocardiography.

"The decision to use a certain valve size would have been changed in about 55 percent of patients in our study if MDCT measurements had been used rather than echocardiography measurements," she said. "This includes patients who were wrongly sized as well as those who would have been disqualified from having TAVI due to the large size of their aortic annulus.”

She also stated that transesophagea/transthoracic echocardiographically derived measurements of the aortic annulus are the current standard for measurement but with the increasing awareness of the discrepancies in measurement between MDCT and echocardiography, more people are using MDCT derived measurements to choose appropriate valve size.

For more information: www.arrs.org

 


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now